QQQ   322.04 (+0.17%)
AAPL   124.91 (-0.75%)
MSFT   232.23 (-0.45%)
FB   263.21 (-1.00%)
GOOGL   2,066.40 (+0.30%)
AMZN   3,155.16 (-1.23%)
TSLA   731.98 (+4.74%)
NVDA   564.30 (-0.24%)
BABA   250.48 (-0.90%)
CGC   36.13 (+2.32%)
GE   13.29 (+5.56%)
MU   90.79 (+2.90%)
NIO   51.60 (+5.07%)
AMD   84.94 (+0.24%)
T   29.48 (+1.03%)
F   12.04 (+3.61%)
ACB   11.73 (+4.64%)
DIS   199.73 (+1.34%)
BA   224.71 (+5.94%)
NFLX   553.85 (+1.41%)
BAC   36.31 (+2.22%)
QQQ   322.04 (+0.17%)
AAPL   124.91 (-0.75%)
MSFT   232.23 (-0.45%)
FB   263.21 (-1.00%)
GOOGL   2,066.40 (+0.30%)
AMZN   3,155.16 (-1.23%)
TSLA   731.98 (+4.74%)
NVDA   564.30 (-0.24%)
BABA   250.48 (-0.90%)
CGC   36.13 (+2.32%)
GE   13.29 (+5.56%)
MU   90.79 (+2.90%)
NIO   51.60 (+5.07%)
AMD   84.94 (+0.24%)
T   29.48 (+1.03%)
F   12.04 (+3.61%)
ACB   11.73 (+4.64%)
DIS   199.73 (+1.34%)
BA   224.71 (+5.94%)
NFLX   553.85 (+1.41%)
BAC   36.31 (+2.22%)
QQQ   322.04 (+0.17%)
AAPL   124.91 (-0.75%)
MSFT   232.23 (-0.45%)
FB   263.21 (-1.00%)
GOOGL   2,066.40 (+0.30%)
AMZN   3,155.16 (-1.23%)
TSLA   731.98 (+4.74%)
NVDA   564.30 (-0.24%)
BABA   250.48 (-0.90%)
CGC   36.13 (+2.32%)
GE   13.29 (+5.56%)
MU   90.79 (+2.90%)
NIO   51.60 (+5.07%)
AMD   84.94 (+0.24%)
T   29.48 (+1.03%)
F   12.04 (+3.61%)
ACB   11.73 (+4.64%)
DIS   199.73 (+1.34%)
BA   224.71 (+5.94%)
NFLX   553.85 (+1.41%)
BAC   36.31 (+2.22%)
QQQ   322.04 (+0.17%)
AAPL   124.91 (-0.75%)
MSFT   232.23 (-0.45%)
FB   263.21 (-1.00%)
GOOGL   2,066.40 (+0.30%)
AMZN   3,155.16 (-1.23%)
TSLA   731.98 (+4.74%)
NVDA   564.30 (-0.24%)
BABA   250.48 (-0.90%)
CGC   36.13 (+2.32%)
GE   13.29 (+5.56%)
MU   90.79 (+2.90%)
NIO   51.60 (+5.07%)
AMD   84.94 (+0.24%)
T   29.48 (+1.03%)
F   12.04 (+3.61%)
ACB   11.73 (+4.64%)
DIS   199.73 (+1.34%)
BA   224.71 (+5.94%)
NFLX   553.85 (+1.41%)
BAC   36.31 (+2.22%)
Log in

HC Wainwright's rating of Revance Therapeutics, Inc. on 10/15/2020

unlock icon Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.